查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813856

SGLT2抑制劑市場規模、佔有率和趨勢分析報告：按藥物、適應症、分銷管道、地區和細分市場預測，2025-2033年

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Type 2 Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

SGLT2抑制劑市場摘要

預計 2024 年全球 SGLT2 抑制劑市場價值將達到 168 億美元，2033 年將達到 289 億美元，2025 年至 2033 年的複合年成長率為 6.19%。

這些用於治療 2 型糖尿病和合併症的藥物因其在控制血糖和降低心血管風險方面的有效性而需求量很大。

由於全球 2 型糖尿病以及心血管疾病和慢性腎臟病等合併症的盛行率不斷上升，市場正在經歷顯著成長。根據國際糖尿病聯盟 (IDF) 的數據，2024 年全球約有 5.89 億成年人將罹患糖尿病，預計到 2050 年將增加至 8.53 億人。日益加重的糖尿病負擔促使醫療系統尋求更有效的治療方法，其中 SGLT2 抑制劑因其控制血糖和保護心血管的雙重益處而廣受歡迎。這些藥物，例如Empagliflozin和Dapagliflozin，在減少糖尿病患者心血管死亡和因心臟衰竭住院方面顯示出顯著益處。此外，SGLT2 抑制劑在治療慢性腎臟病中的作用越來越受到認可，這推動了進一步的市場需求，FDA核准Dapagliflozin用於治療非糖尿病患者的慢性腎臟病是 2020 年的主要適應症擴展。

目錄

第1章調查方法與範圍

第2章執行摘要

3. SGLT2抑制劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • SGLT2抑制劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析
    • 目標人群分析

第4章 SGLT2抑制劑市場：藥物估價與趨勢分析

  • 全球 SGLT2 抑制劑市場：製藥儀表板
  • 全球SGLT2抑制劑市場：藥物變異分析
  • 全球 SGLT2 抑制劑市場（按藥物和收益）
  • Jardiance（Empagliflozin）
  • Farxiga（Dapagliflozin）
  • Invokana（Canagliflozin）
  • Impefa（索格列淨）
  • Qtern（Dapagliflozin/沙格列汀）
  • 其他SGLT2抑制劑

第5章 SGLT2抑制劑市場：適應症與趨勢分析

  • 全球 SGLT2 抑制劑市場：適應症儀表板
  • 全球SGLT2抑制劑市場：適應症差異分析
  • 按適應症分類的收益
  • 2型糖尿病
  • 心血管系統
  • 慢性腎臟病（CKD）
  • 其他

第6章：SGLT2抑制劑市場：通路評估與趨勢分析

  • 全球 SGLT2 抑制劑市場：分銷通路儀表板
  • 全球 SGLT2 抑制劑市場：通路變化分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥局
  • 網路藥局

7. SGLT2抑制劑市場：按藥物、適應症和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 市場規模、預測趨勢分析，2021-2033年：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2023
    • Boehringer Ingelheim International GmbH.
    • AstraZeneca
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.（Janssen Pharmaceuticals, Inc.）
    • TheracosBio, LLC
    • Lexicon Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Glenmark Pharmaceuticals Ltd
Product Code: GVR-4-68040-322-4

SGLT2 Inhibitors Market Summary

The global SGLT2 inhibitors market size was estimated at USD 16.8 billion in 2024 and is projected to reach USD 28.9 billion by 2033, growing at a CAGR of 6.19% from 2025 to 2033. These drugs, used for Type 2 diabetes and comorbidities, are in high demand due to their effectiveness in glycemic control and cardiovascular risk reduction.

The market is experiencing significant growth due to the increasing global prevalence of Type 2 diabetes, along with related comorbidities such as cardiovascular diseases and chronic kidney disease. According to the International Diabetes Federation (IDF), nearly 589 million adults worldwide were living with diabetes in 2024, a figure that is expected to rise to 853 million by 2050. This growing burden of diabetes is prompting healthcare systems to seek more effective treatment options, with SGLT2 inhibitors gaining popularity due to their dual benefits of glycemic control and cardiovascular protection. These drugs, such as empagliflozin and dapagliflozin, have shown significant efficacy in reducing cardiovascular mortality and hospitalizations for heart failure in diabetic patients. Furthermore, the increasing recognition of the role of SGLT2 inhibitors in treating chronic kidney disease is driving further market demand, with the FDA's approval of dapagliflozin for chronic kidney disease in non-diabetic patients marking a notable expansion of its indications in 2020.

Global SGLT2 Inhibitors Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global SGLT2 Inhibitors market report based on drug, indication, distribution channel,and region:

  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Jardiance (empagliflozin)
  • Farxiga (dapagliflozin)
  • Invokana (canagliflozin)
  • Inpefa (sotagliflozin)
  • Qtern (dapagliflozin/saxagliptin)
  • Other SGLT2 Inhibitors
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Type 2 Diabetes
  • Cardiovascular
  • Chronic Kidney Disease (CKD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug and Indication outlook
    • 2.2.2. Distribution Channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target disease
      • 3.2.1.2. Technological advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of drug development
      • 3.2.2.2. Stringent regulatory policies for drug approval
  • 3.3. SGLT2 Inhibitors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

  • 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
  • 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
  • 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
  • 4.4. Jardiance (empagliflozin)
    • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Farxiga (dapagliflozin)
    • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Invokana (canagliflozin)
    • 4.6.1. Invokana (canagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7. Inpefa (sotagliflozin)
    • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8. Qtern (dapagliflozin/saxagliptin)
    • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.9. Other SGLT2 Inhibitors
    • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

  • 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
  • 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
  • 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
  • 5.4. Type 2 Diabetes
    • 5.4.1. Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cardiovascular
    • 5.5.1. Cardiovascular market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Chronic Kidney Disease (CKD)
    • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
  • 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
  • 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Boehringer Ingelheim International GmbH.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AstraZeneca
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. TheracosBio, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lexicon Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Eli Lilly and Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bristol-Myers Squibb Company
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Glenmark Pharmaceuticals Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 4 North America SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 U.S. SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 7 U.S. SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 Canada SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 10 Canada SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 Mexico SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 13 Mexico SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 17 Europe SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 19 Germany SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 20 Germany SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 UK SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 23 UK SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 France SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 26 France SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 27 France SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Italy SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 29 Italy SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 31 Spain SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 32 Spain SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Denmark SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 35 Denmark SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Sweden SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 38 Sweden SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 40 Norway SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 41 Norway SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 China SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 48 China SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 49 China SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Japan SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 51 Japan SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 53 India SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 54 India SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 55 India SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 South Korea SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 57 South Korea SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 Australia SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 60 Australia SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Thailand SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 63 Thailand SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Latin America SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 67 Latin America SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 69 Brazil SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 70 Brazil SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 72 Argentina SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 73 Argentina SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 MEA SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 77 MEA SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 South Africa SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 80 South Africa SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 85 UAE SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 86 UAE SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 SGLT2 Inhibitors market: market outlook
  • Fig. 14 SGLT2 Inhibitors competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 SGLT2 Inhibitors market driver impact
  • Fig. 18 SGLT2 Inhibitors market restraint impact
  • Fig. 19 SGLT2 Inhibitors market: Drug movement analysis
  • Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways
  • Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Invokana (canagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 SGLT2 Inhibitors market: Indication movement analysis
  • Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways
  • Fig. 30 Type 2 diabetes market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Cardiovascular market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis
  • Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Retail pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Online pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis
  • Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways
  • Fig. 41 Global SGLT2 Inhibitors market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market share of key market players - SGLT2 Inhibitors market